ERBB2 and breast cancer: In EGF30008, which randomized patients with HR+ BC (n = 1171) to receive letrozole plus either lapatinib or placebo, the predetermined HR+/HER2+ subgroup (n = 219) had improved PFS (8.2 vs. 3.0 months; hazard ratio 0.71; 95% CI 0.53‒0.96; p = 0.019) and clinical benefits rate (CBR; stable or responding disease ≥6 months: 48% vs. 29%; odds ratio (OR) 0.4; 95% CI 0.2‒0.8; p = 0.003) with dual therapy [59].